|
US2016333356A1
|
|
Oligonucleotide modulators of the toll-like receptor pathway
|
|
US2016355805A1
|
|
Double stranded oligonucleotide compounds comprising positional modifications
|
|
CN106661579A
|
|
Methods and compositions for preventing ischemia reperfusion injury in organs
|
|
GB201413532D0
|
|
Combination therapy for treating hearing disorders
|
|
GB201413534D0
|
|
Otic compositions and uses thereof
|
|
GB201413533D0
|
|
Combination therapy for treating disorders of the vestibular system
|
|
GB201413538D0
|
|
Ophthalmic compositions and uses thereof
|
|
US2015259676A1
|
|
Double-stranded nucleic acid compounds
|
|
US2015203845A1
|
|
Double-stranded oligonucleotide molecules to P53 and methods of use thereof
|
|
AU2013315524A1
|
|
Double-stranded oligonucleotide molecules to p53 and methods of use thereof
|
|
BR112014016937A2
|
|
combination therapy for the treatment of hearing and balance disorders
|
|
CA2858627A1
|
|
Double-stranded rna compounds to casp2 and uses thereof
|
|
EP2776565A1
|
|
Methods and compositions for treating diseases, disorders or injury of the nervous system
|
|
CN103917647A
|
|
Methods and compositions for neuroprotection
|
|
US2013131143A1
|
|
RTP801L siRNA compounds and methods of use thereof
|
|
AU2012232948A1
|
|
Oligoribonucleotides and Methods of Use Thereof for Treatment of Alopecia, Acute Renal Failure and Other Diseases
|
|
CA2842954A1
|
|
Double-stranded oligonucleotide compounds for treating hearing and balance disorders
|
|
NZ614712A
|
|
Oligonucleotide modulators of the toll-like receptor pathway
|
|
KR20140042792A
|
|
Compositions and methods for treating lung disease and injury
|
|
WO2012078536A2
|
|
Double stranded oligonucleotide compounds comprising threose modifications
|
